These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 28410749

  • 1. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
    Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group.
    Atherosclerosis; 2017 Jun; 261():144-152. PubMed ID: 28410749
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
    Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S.
    Int J Mol Sci; 2019 Nov 06; 20(22):. PubMed ID: 31698825
    [Abstract] [Full Text] [Related]

  • 3. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S.
    Cardiovasc Diabetol; 2021 May 04; 20(1):96. PubMed ID: 33947390
    [Abstract] [Full Text] [Related]

  • 4. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
    Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T, K-877-04 Study Group.
    Atherosclerosis; 2016 Jun 04; 249():36-43. PubMed ID: 27062408
    [Abstract] [Full Text] [Related]

  • 5. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S, Masuda D, Matsuzawa Y.
    Curr Atheroscler Rep; 2020 Jan 23; 22(1):5. PubMed ID: 31974794
    [Abstract] [Full Text] [Related]

  • 6. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C, Masuda D, Koseki M, Yamashita S.
    Cardiovasc Diabetol; 2020 Nov 27; 19(1):201. PubMed ID: 33246467
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group.
    J Atheroscler Thromb; 2018 Jun 01; 25(6):521-538. PubMed ID: 29628483
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S.
    Diabetes Care; 2018 Mar 01; 41(3):538-546. PubMed ID: 29298800
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
    Ginsberg HN, Hounslow NJ, Senko Y, Suganami H, Bogdanski P, Ceska R, Kalina A, Libis RA, Supryadkina TV, Hovingh GK.
    Diabetes Care; 2022 Apr 01; 45(4):898-908. PubMed ID: 35238894
    [Abstract] [Full Text] [Related]

  • 16. SPPARM alpha: the Lazarus effect.
    Fruchart JC, Santos RD.
    Curr Opin Lipidol; 2019 Dec 01; 30(6):419-427. PubMed ID: 31577610
    [Abstract] [Full Text] [Related]

  • 17. Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
    Kastelein JJ, Hallén J, Vige R, Fraser DA, Zhou R, Hustvedt SO, Orloff DG, Bays HE.
    Cardiology; 2016 Dec 01; 135(1):3-12. PubMed ID: 27160246
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.